Welcome to our dedicated page for Ensysce Biosciences news (Ticker: ENSC), a resource for investors and traders seeking the latest updates and insights on Ensysce Biosciences stock.
Ensysce Biosciences, Inc. reports developments as a clinical-stage pharmaceutical company focused on pain and central nervous system therapeutics designed to reduce opioid abuse and overdose risk. Its recurring updates center on the TAAP™ (Trypsin-Activated Abuse Protection) prodrug platform, the MPAR® (Multi-Pill Abuse Resistance) overdose-protection platform, and product candidates including PF614 and PF614-MPAR.
Company news also covers clinical-study progress, FDA-related designations and regulatory engagement, peer-reviewed data, scientific conference presentations, intellectual-property updates, financing transactions, financial results, Nasdaq compliance matters, board and governance changes, and strategic-review disclosures.
Ensysce Biosciences (NASDAQ:ENSC) hosted a well-attended symposium titled "Pain Management, RE-Invented: A New Era for Analgesia" at PAINWeek 2025 in Las Vegas. The symposium, which drew approximately 400 attendees, featured presentations from leading pain medicine experts highlighting the company's innovative TAAP™ and MPAR® technologies.
The event showcased Ensysce's approach to developing safer opioids, featuring their lead candidate PF614. The technology uniquely uses the body's chemistry to activate pain relief with proper dosing while preventing overdose. Dr. William Schmidt presented data on PF614 and outlined plans for an upcoming Phase 3 trial in acute post-surgical pain.
Ensysce Biosciences (NASDAQ:ENSC) announced that Chief Commercial Officer Geoff Birkett will chair the Fierce New Product Planning Summit 2025, scheduled for September 8-11, 2025, in Philadelphia. Birkett will deliver opening remarks and present a case study on successful product launches.
The summit focuses on helping product planning teams make informed, value-based decisions for commercial success. At Ensysce, Birkett is leading the launch preparations for PF614, the company's first-in-class analgesic designed to combat severe pain while reducing abuse and overdose risks.
Birkett brings extensive experience from leadership roles at Eli Lilly, Lundbeck, and AstraZeneca, where he successfully launched several groundbreaking medicines in pain, addiction, and neuroscience.
Ensysce Biosciences (NASDAQ:ENSC) reported significant progress in Q2 2025 for its innovative opioid therapy programs. The company initiated a pivotal Phase 3 trial for PF614, its lead candidate for severe pain with built-in abuse deterrence. Additionally, Ensysce completed enrollment for Part 2 of the PF614-MPAR-102 study, advancing its overdose protection program.
Key financial highlights include a cash position of $2.2 million as of June 30, 2025, receipt of a $5.3 million NIDA grant installment, and R&D expenses of $1.9 million. The company reported a net loss of $1.7 million for Q2 2025, an improvement from the $2.0 million loss in Q2 2024.
The company's pipeline includes PF614 (TAAP™ technology) and PF614-MPAR (combining TAAP™ and MPAR® technologies), both designed to provide safer opioid therapies. Ensysce also advanced its OUD program with PF9001 as the lead candidate for opioid use disorder treatment.
Ensysce Biosciences (NASDAQ:ENSC) reported positive feedback from the FDA regarding PF614-MPAR, their breakthrough opioid analgesic with built-in overdose protection. The July 23, 2025 FDA meeting focused on achieving overdose protection labeling and confirmed eligibility for a streamlined 505(b)(2) regulatory pathway.
PF614-MPAR, which has received FDA's Breakthrough Therapy designation, utilizes Ensysce's proprietary TAAP™ and MPAR® technologies to maintain pain relief while automatically activating overdose protection if prescribed doses are exceeded. The development is supported by NIDA grants through May 2027.
Ensysce Biosciences (NASDAQ:ENSC) has launched its pivotal Phase 3 study of PF614, a next-generation opioid designed for severe pain management with built-in abuse and overdose protection. The study, designated PF614-301, will evaluate the drug's efficacy and safety in treating moderate to severe pain following abdominoplasty.
The company has partnered with Rho, Inc., a clinical research organization with extensive CNS and pain study expertise, having managed over 90 neurology trials across 840 sites in the past five years. The study aims to demonstrate PF614's ability to provide effective post-surgical pain relief while offering a safer alternative to conventional opioids.
Ensysce Biosciences (NASDAQ:ENSC) has announced full enrollment of Part 2 in their PF614-MPAR-102 clinical study, focusing on evaluating food effects on their MPAR overdose protection technology. The study is supported by a three-year NIDA grant extending through May 2027.
PF614-MPAR, which has received FDA Breakthrough Therapy designation, combines Ensysce's proprietary TAAP™ and MPAR® technologies to provide pain relief with built-in overdose protection. The technology is designed to maintain therapeutic efficacy while preventing overdose when doses exceed prescribed amounts.
Ensysce Biosciences (NASDAQ:ENSC) has appointed Tracy Hysong, CCRA as Senior Director of Regulatory Affairs. Hysong, a Certified Clinical Research Associate, brings extensive regulatory experience from UC Davis, where she helped establish the Clinical Trials Office. This strategic hire comes as Ensysce prepares for multiple clinical milestones:
- Initiating Phase 3 pivotal study for PF614 with planned NDA submission in 2026 - Ongoing clinical studies for overdose-protected pain medicine PF614-MPAR - Preparing IND Application and Phase 1 study for novel PF9001 opioid use disorder (OUD) treatment
The appointment strengthens Ensysce's regulatory capabilities as it manages three current INDs and prepares for a fourth IND submission for its OUD treatment.